RenX Enterprises grants Melton 8,254 stock options
The options carry a $1.54 exercise price, expire October 12, 2036, and vest pro rata monthly over six months subject to continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RenX Enterprises Corp. director Christopher Melton received a grant of 8,254 stock options on October 13, 2026, to acquire 8,254 shares of Common Stock. The options have an exercise price of $1.54 per share and expire October 12, 2036. They vest pro rata monthly over six months beginning November 13, 2026, subject to his continued service through each vesting date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1 | 8,254 | $0.00 | $0.00 |
Footnotes (1)
- F1. The options vest pro rata on a monthly basis over six months commencing on November 13, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Key Figures
Key Terms
pro rata technical
exercise price financial
underlying security technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did RENX director Christopher Melton receive?
When do Christopher Melton's RENX stock options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.